Cardio Lab · DeCure for X
DeCure's autonomous Cardio AI scientist is researching a drug-repurposing hypothesis for atrial septal defect 9 — screening already-approved drugs against its 1-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
No approved-drug candidate for atrial septal defect 9 is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
In adults over 40 with isolated atrial septal defects, a retrospective study of 179 patients (84 surgical, 95 medical) over a mean follow-up of 8.9 years found that surgical closure reduced all-cause mortality (relative risk 0.31, 95% CI 0.11 to 0.85). Adjusted 10-year survival was 95% for surgical patients versus 84% for medical patients. Surgical treatment also prevented functional deterioration measured by New York Heart Association class (relative risk 0.21, 95% CI 0.08 to 0.55). However, the incidence of new atrial arrhythmias or cerebrovascular insults did not differ significantly between the two groups.
In children and adolescents under 14, a prospective non-randomised study compared percutaneous closure (75 patients) with surgical closure (105 patients). Technical success was 100% in both groups with no deaths. Complications, mostly minor, occurred in 68% of the surgical group and 4% of the percutaneous group (p < 0.001). Rates of total occlusion or non-significant residual shunts were similar. Median hospital stay was 1.2 days for percutaneous and 8.4 days for surgical patients (p < 0.001). The authors concluded that percutaneous treatment has lower morbidity and shorter hospital stay and should be regarded as the method of choice for selected patients.
A 2006 review noted that patients with isolated atrial septal defects have benefited from advances in diagnosis and management, but focused on adolescent and adult patients with sizeable defects without other major cardiac anomalies. A 2020 review of aetiology stated that although atrial septal defects are treatable, the underlying cause remains unclear and research must continue.
What is still missing is a clear understanding of the causes of atrial septal defects, which limits prevention and stratification. The existing comparative studies are observational and non-randomised, and the adult surgical trial is from 1995 with no contemporary medical comparator. No drug therapy is mentioned in any of these abstracts.
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
AbstractP atients with isolated atrial septal defects (ASDs) have benefited from important recent advances in the diagnosis, evaluation, and management of their conditions. This review will focus on adolescent and adult patients with sizeable ASDs who do not have other major associated cardiac defects.
https://doi.org/10.1161/circulationaha.105.592055AbstractBACKGROUND: The surgical closure of an atrial septal defect is frequently recommended for patients over 40 years of age. However, the prognosis for such patients with unrepaired defects is largely unknown, and the outcome for patients operated on after the fourth decade of life has not yet been compared with that for medically treated patients in a controlled follow-up study. METHODS: In a retrospective study, we examined the clinical course of 179 consecutive patients with isolated atrial septal defects diagnosed after the age of 40. The 84 patients (47 percent) who underwent surgical repair were compared with the 95 patients (53 percent) who were treated medically. The mean (+/-SD) follow-up period was 8.9 +/- 5.2 years (range, 1 to 26). RESULTS: Multivariate analysis revealed that surgical closure of the defect significantly reduced mortality from all causes (relative risk, 0.31; 95 percent confidence interval, 0.11 to 0.85). The adjusted 10-year survival rate of surgically treated patients was 95 percent, as compared with 84 percent for the medically treated patients. In addition, surgical treatment prevented functional deterioration, as measured by the New York Heart Association class (relative risk, 0.21; 95 percent confidence interval, 0.08 to 0.55). However, the incidence of new atrial arrhythmias or of cerebrovascular insults in the two groups was not significantly different. CONCLUSIONS: The surgical repair of an atrial septal defect in patients over 40 years of age, as compared with medical therapy, increases long-term survival and limits the deterioration of function due to heart failure. However, surgically treated patients should be followed closely for the onset of atrial arrhythmias so as to reduce the risk of thromboembolic complications.
https://doi.org/10.1056/nejm199508243330801AbstractBACKGROUND: There is a scarcity of data comparing percutaneous and surgical closure of the secundum atrial septal defect (ASD). OBJECTIVES: Assessment of safety and efficacy of both methods of treatment in a referral center affiliated with the Ministry of Health. METHODS: Observational, prospective, non-randomized study of two cohorts of children and adolescents younger than 14 years, treated by catheterization or surgery. Data was collected prospectively in the percutaneous group (A) and retrospectively in the surgical group (B). RESULTS: A total of 75 patients (pts) were enrolled in group A from April 2009 to October 2011 and 105 pts were treated in group B from January 2006 to January 2011. Age was older and weight was higher in group B and the ASD diameter was similar in both groups. Technical success was achieved in all procedures and there were no deaths. Complications (most minor) occurred in 68% of group B and 4% of A (p < 0.001). Rates of total occlusion or non-significant residual shunts were similar in both groups. Median hospitalization time was 1.2 days in group A and 8.4 days in group B (p < 0.001). CONCLUSION: Both treatment modalities are safe and effective, showing excellent outcomes. However, the percutaneous treatment has lower morbidity and shorter in-hospital stay length. These observations support the concept that percutaneous treatment of atrial septal defects should be regarded as the method of choice to manage selected patients with this condition.
https://doi.org/10.5935/abc.20130059AbstractAtrial septal defect is caused by malformation of the septum between left and right atrium. This paper will firstly review the embryology and classification of atrial septal defect, then the etiology of atrial septal defect will be discussed according to various studies. Even atrial septal defects are treatable, the underlying cause of such defects is not clear, therefore, the research into them must be continued.
https://doi.org/10.25236/fmsr.2020.020202Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
